Evgen Pharma PLC Directorate Change (3902L)
30 Aprile 2020 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 3902L
Evgen Pharma PLC
30 April 2020
Evgen Pharma plc
("Evgen Pharma" or the "Company")
Directorate Change
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces the resignation with immediate effect of Dr.
Stephen Franklin as Chief Executive Officer of the Company. Having
led Evgen for over 12 years Steve has, with the support of the
Board, decided to pursue other opportunities.
Barry Clare will become Executive Chairman on a temporary basis
until a new CEO is appointed with the appropriate experience to
take Evgen through the next exciting stages of its development.
Barry, together with our strong group of Non-Executive Directors;
Susan Clement-Davies, Sue Foden and Alan Barge, will support the
executive team on business development and pre-clinical and
clinical projects. The Company remains committed to developing
sulforaphane-based medicines for the treatment of breast cancer and
multiple other diseases and continues to collaborate with its
various hospital and university partners.
The search for a replacement to fill the role is underway and
the Company will update the market in due course.
Barry Clare, Non-Executive Chairman, said : "On behalf of the
Board, I would like to extend our sincere gratitude to Steve for
all his efforts and his guidance since Evgen's inception. His
contribution to the Company over the years has been invaluable and
we would like to offer our huge thanks for all his support and hard
work. We wish him all the best in his future endeavours."
The information communicated in this announcement is inside
information for the purposes of Article 7 of EU Regulation
596/2014.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane / Manasa Patil (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases . The Company's core technology is Sulforadex
(R), a method for synthesising and stabilising the naturally
occurring compound sulforaphane and novel proprietary analogues
based on sulforaphane. The lead product, SFX-01, is a patented
composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFLFSRSRIAFII
(END) Dow Jones Newswires
April 30, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024